TIDMPRTC
PureTech Health PLC
10 March 2020
10 March 2020
PureTech Health plc
PureTech Affiliate Gelesis Named One of the World's Most
Innovative Companies for 2020 by Fast Company
List honours businesses making most profound impact on both
industry and culture
PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company"),
a clinical stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, is pleased to note that its affiliate,
Gelesis, was named to Fast Company's prestigious annual list of the
World's Most Innovative Companies for 2020. The list honours the
businesses making the most profound impact on both industry and
culture, and Gelesis earned the standing of #5 in the biotech
category.
Eric Elenko, PhD, chief innovation officer at PureTech, said:
"We congratulate Gelesis on this noteworthy recognition from Fast
Company, which honours the top companies from across the world. We
are very proud of Gelesis' progress to date, and we look forward to
the US commercialisation of Plenity (TM) later this year."
The full text of the announcement from Gelesis is as
follows:
Gelesis Named One of the World's Most Innovative Companies for
2020 by Fast Company
BOSTON - March 10, 2020 - Gelesis , a biotechnology company
developing a novel hydrogel platform technology to treat obesity
and other chronic diseases related to the gastrointestinal (GI)
tract, has been named to Fast Company's prestigious annual list of
the World's Most Innovative Companies for 2020.
The list honours the businesses making the most profound impact
on both industry and culture, showcasing a variety of ways to
thrive in today's fast-changing world. Gelesis earned the standing
of #5 in the biotech category. This year's full Most Innovative
Companies list features 434 businesses from 39 countries.
The first product based on Gelesis' patented hydrogel, Plenity
(TM) , an orally administered, non-systemic and non-stimulant aid
to weight management, was cleared for use by the FDA in adults with
a Body Mass Index (BMI) of 25-40 kg/m(2) , when used in conjunction
with diet and exercise. It is the only prescription weight
management product indicated for use by overweight adults with a
BMI as low as 25 kg/m(2) , making it available for the largest
number of adults affected by overweight and obesity of any
prescription weight-management aid.
Gelesis' product pipeline includes possible treatments for a
range of GI diseases, including NASH and NAFLD, type 2 diabetes,
chronic constipation, and weight management in adolescent
overweight and obesity.
"Our mission is to improve the lives of the millions of people
struggling with excess weight and it's an incredible honour to be
recognised for that work," said Yishai Zohar, CEO and founder of
Gelesis. "This recognition from Fast Company kicks off an exciting
year with the initial commercial launch of Plenity later in
2020."
Fast Company's editors and writers sought out the most
groundbreaking businesses on the planet and across myriad
industries. They also judged nominations received through their
application process.
The World's Most Innovative Companies is Fast Company's
signature franchise and one of its most highly anticipated
editorial efforts of the year. It provides both a snapshot and a
road map for the future of innovation across the most dynamic
sectors of the economy.
"At a time of increasing global volatility, this year's list
showcases the resilience and optimism of businesses across the
world. These companies are applying creativity to solve challenges
within their industries and far beyond," said Fast Company senior
editor Amy Farley, who oversaw the issue with deputy editor David
Lidsky.
Fast Company's Most Innovative Companies issue (March/April
2020) is now available online at
fastcompany.com/most-innovativecompanies/2020, as well as in app
form via iTunes and on newsstands beginning March 17, 2020. The
hashtag is #FCMostInnovative.
ABOUT GELESIS
Gelesis is developing a novel hydrogel platform technology to
treat overweight and obesity and chronic diseases related to the GI
pathway. Gelesis' proprietary approach is designed to act
mechanically in the GI pathway to potentially alter the course of
certain chronic diseases. In April 2019, Gelesis received FDA
clearance for its lead product candidate, Plenity(TM), as an aid
for weight management in overweight and obese adults with a Body
Mass Index (BMI) of 25-40 kg/m(2) , when used in conjunction with
diet and exercise. Gelesis anticipates Plenity will be available by
prescription in the US in the second half of 2020. Additionally,
Gelesis is developing its second investigational candidate,
Gelesis200, a hydrogel optimised for weight loss and glycaemic
control in patients with type 2 diabetes and prediabetes. Novel
hydrogel mechanotherapeutics based on the Gelesis platform
technology are also being advanced in other GI inflammatory
conditions, such as non-alcoholic steatohepatitis (NASH) and
Chronic Idiopathic Constipation (CIC).
The Gelesis executive and advisory team includes some of the
world's leading experts in obesity, materials science, chronic
disease research, and commercialisation. Gelesis was co-founded by
PureTech Health (LSE: PRTC), a clinical-stage biotherapeutics
company dedicated to discovering, developing and commercialising
highly differentiated medicines for devastating diseases. For more
information, visit gelesis.com or connect with us on Twitter
@GelesisInc.
ABOUT PLENITY(TM)
Plenity(TM) is an oral, non-systemic, superabsorbent hydrogel
which has received FDA clearance as an aid in weight management in
overweight and obese adults with a BMI of 25-40 kg/m(2) , when used
in conjunction with diet and exercise. It is made by cross-linking
two naturally derived building blocks, modified cellulose and
citric acid, that create a three-dimensional matrix. Plenity
particles rapidly absorb water in the stomach and homogenously mix
with ingested foods. Rather than forming one large mass, it creates
thousands of small individual gel pieces with the elasticity
(firmness) of solid plant-based foods (e.g., vegetables) without
caloric value. The Plenity hydrogel increases the volume and
elasticity of the stomach and small intestine contents and induces
a feeling of fullness and satiety. Once it arrives in the large
intestine, the hydrogel is partially broken down by enzymes and
loses its three-dimensional structure along with most of its
absorption capacity. The released water is reabsorbed in the large
intestine, and the remaining cellulosic material is eliminated
through the body's natural digestive processes. PLENITY is
considered a medical device because it achieves its primary
intended purpose through mechanical modes of action consistent with
mechanobiology constructs. For more information, visit
myplenity.com .
Important Safety Information
-- PLENITY is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl
fumarate, gelatin or titanium oxide.
-- PLENITY may alter the absorption of medications.
-- Avoid use in patients with the following conditions: esophageal anatomic anomalies, including webs, diverticuli,
and rings; suspected strictures (such as patients with Crohn's disease); or complications from prior
gastrointestinal (GI) surgery that could affect GI transit and motility.
-- Use with caution in patients with active GI conditions such as gastro-esophageal reflux disease (GERD), ulcers or
heartburn.
-- Overall, the most common treatment related adverse events were GI-related with 38% of adults in the PLENITY group
and 28% of adults in the placebo group.
-- The overall incidence of adverse events (AEs) in the PLENITY group was no different than the placebo group.
Rx Only. For the safe and proper use of PLENITY, refer to the
Instructions for Use.
ABOUT FAST COMPANY
Fast Company is the only media brand fully dedicated to the
vital intersection of business, innovation, and design, engaging
the most influential leaders, companies, and thinkers on the future
of business. Since 2011, Fast Company has received some of the most
prestigious editorial and design accolades, including the American
Society of Magazine Editors (ASME) National Magazine Award for
"Magazine of the Year," Adweek's Hot List for "Hottest Business
Publication," and six gold medals and 10 silver medals from the
Society of Publication Designers. The editor-in-chief is Stephanie
Mehta and the publisher is Amanda Smith. Headquartered in New York
City, Fast Company is published by Mansueto Ventures LLC, along
with our sister publication Inc., and can be found online at
www.fastcompany.com.
About PureTech Health
PureTech is a clinical stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's affiliates, is
comprised of 23 product candidates and one product that has been
cleared by the US Food and Drug Administration (FDA). All of the
underlying programmes and platforms that resulted in this pipeline
of product candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADBGDXDDGDGGC
(END) Dow Jones Newswires
March 10, 2020 06:00 ET (10:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024